Moving forward fast – ASPIVIX is finishing the 2022 with a new investment and a generous grant

Leading the Series A+ funding round, HEMEX is proud to announce that our portfolio company ASPIVIX not only secured $5M, but also received a large EUREKA-EUROSTARS grant, co-founded by Innosuisse. ASPIVIX will use the investment to enter the European and US market. Additionally, the company will invest in R&D to expand its existing product line and generate additional clinical data in the US. 





HEMEX is committed to changing the future of healthcare by guiding the most promising European startups through each and every step to bring innovative pharmaceuticals, medical devices, and in vitro diagnostics to the market. Headquartered close to the thriving Basel global Life Sciences hub, the goal at HEMEX is to ensure startups have access to a wide range of tailored products, practical solutions, and fundraising support. This empowers the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare. For more information, visit